{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:06:29Z","timestamp":1793048789130,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s11899-024-00737-8","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T03:21:21Z","timestamp":1724728881000},"page":"197-207","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Systemic Mastocytosis: State of the Art"],"prefix":"10.1007","volume":"19","author":[{"given":"Isabel","family":"Farmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti H.","family":"Radia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"737_CR1","doi-asserted-by":"publisher","unstructured":"Piris-Villaespesa, M. and Alvarez-Twose, I. (2020) \u2018Systemic mastocytosis: Following the tyrosine kinase inhibition roadmap\u2019, Frontiers in Pharmacology, 11. https:\/\/doi.org\/10.3389\/fphar.2020.00443.","DOI":"10.3389\/fphar.2020.00443"},{"key":"737_CR2","doi-asserted-by":"publisher","unstructured":"Gotlib, J. et al. (2022) \u2018Proposed European Competence Network on mastocytosis\u2014American initiative in mast cell diseases (ECNM-AIM) response criteria in advanced systemic mastocytosis\u2019, The Journal of Allergy and Clinical Immunology: In Practice, 10(8). https:\/\/doi.org\/10.1016\/j.jaip.2022.05.034.","DOI":"10.1016\/j.jaip.2022.05.034"},{"issue":"5","key":"737_CR3","doi-asserted-by":"publisher","first-page":"100466","DOI":"10.1016\/j.modpat.2024.100466","volume":"37","author":"JK Choi","year":"2024","unstructured":"Choi JK, et al. Fifth edition of the World Health Organization classification of tumors of the hematopoietic and lymphoid tissues: Acute lymphoblastic leukemias, mixed-phenotype acute leukemias, myeloid\/lymphoid neoplasms with eosinophilia, dendritic\/histiocytic neoplasms, and genetic tumor syndromes. Mod Pathol. 2024;37(5):100466. https:\/\/doi.org\/10.1016\/j.modpat.2024.100466.","journal-title":"Mod Pathol"},{"issue":"4","key":"737_CR4","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.iac.2023.05.001","volume":"43","author":"C Akin","year":"2023","unstructured":"Akin C. Tyrosine kinase inhibitors in non-advanced systemic mastocytosis. Immunol Allergy Clin North Am. 2023;43(4):743\u201350. https:\/\/doi.org\/10.1016\/j.iac.2023.05.001.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"20","key":"737_CR5","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1002\/cncr.34420","volume":"128","author":"RA Mesa","year":"2022","unstructured":"Mesa RA, et al. Patient-reported outcomes among patients with systemic mastocytosis in routine clinical practice: Results of the touchstone SM patient survey. Cancer. 2022;128(20):3691\u20139. https:\/\/doi.org\/10.1002\/cncr.34420.","journal-title":"Cancer"},{"key":"737_CR6","doi-asserted-by":"publisher","unstructured":"Buonomo, A., Nucera, E. and Criscuolo, M. (2022) \u2018Treatment of indolent and advanced systemic mastocytosis\u2019,\u00a0Mediterranean Journal of Hematology and Infectious Diseases, 14(1). https:\/\/doi.org\/10.4084\/mjhid.2022.040.","DOI":"10.4084\/mjhid.2022.040"},{"issue":"4","key":"737_CR7","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s11547-020-01306-8","volume":"126","author":"A Leone","year":"2020","unstructured":"Leone A, et al. Systemic mastocytosis revisited with an emphasis on skeletal manifestations. Radiol Med (Torino). 2020;126(4):585\u201398. https:\/\/doi.org\/10.1007\/s11547-020-01306-8.","journal-title":"Radiol Med (Torino)"},{"issue":"1","key":"737_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00428-022-03423-3","volume":"482","author":"RJ Leguit","year":"2022","unstructured":"Leguit RJ, et al. The international consensus classification of mastocytosis and related entities. Virchows Arch. 2022;482(1):99\u2013112. https:\/\/doi.org\/10.1007\/s00428-022-03423-3.","journal-title":"Virchows Arch"},{"issue":"4","key":"737_CR9","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/ajh.26118","volume":"96","author":"A Pardanani","year":"2021","unstructured":"Pardanani A. Systemic mastocytosis in adults: 2021 update on diagnosis, risk stratification and management. Am J Hematol. 2021;96(4):508\u201325. https:\/\/doi.org\/10.1002\/ajh.26118.","journal-title":"Am J Hematol"},{"key":"737_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejim.2016.01.005","volume":"30","author":"MAW Hermans","year":"2016","unstructured":"Hermans MAW, et al. Systemic mastocytosis: A cohort study on clinical characteristics of 136 patients in a large tertiary centre. Eur J Intern Med. 2016;30:25\u201330. https:\/\/doi.org\/10.1016\/j.ejim.2016.01.005.","journal-title":"Eur J Intern Med"},{"issue":"4","key":"737_CR11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/bjh.12916","volume":"166","author":"SS Cohen","year":"2014","unstructured":"Cohen SS, et al. Epidemiology of systemic mastocytosis in Denmark. Br J Haematol. 2014;166(4):521\u20138. https:\/\/doi.org\/10.1111\/bjh.12916.","journal-title":"Br J Haematol"},{"key":"737_CR12","doi-asserted-by":"publisher","unstructured":"L\u00fcbke, J.\u00a0et al.\u00a0(2024) \u2018Serum chemistry profiling and prognostication in systemic mastocytosis: A registry-based study of the ECNM and Grem\u2019,\u00a0Blood Advances\u00a0[Preprint]. https:\/\/doi.org\/10.1182\/bloodadvances.2024012756.","DOI":"10.1182\/bloodadvances.2024012756"},{"issue":"1","key":"737_CR13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/bjh.13789","volume":"172","author":"L S\u00e1nchez-Mu\u00f1oz","year":"2015","unstructured":"S\u00e1nchez-Mu\u00f1oz L, et al. Diagnosis and classification of mastocytosis in non-specialized versus reference centres: A Spanish network on mastocytosis (rema) study on 122 patients. Br J Haematol. 2015;172(1):56\u201363. https:\/\/doi.org\/10.1111\/bjh.13789.","journal-title":"Br J Haematol"},{"key":"737_CR14","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1172\/jci118337","volume":"96","author":"LB Schwartz","year":"1995","unstructured":"Schwartz LB, et al. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. Journal of Clinical Investigation. 1995;96:2702\u201310. https:\/\/doi.org\/10.1172\/jci118337.","journal-title":"Journal of Clinical Investigation"},{"issue":"8","key":"737_CR15","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/ajh.26984","volume":"98","author":"G Garcia-Manero","year":"2023","unstructured":"Garcia-Manero G. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and Management. Am J Hematol. 2023;98(8):1307\u201325. https:\/\/doi.org\/10.1002\/ajh.26984.","journal-title":"Am J Hematol"},{"issue":"8","key":"737_CR16","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1002\/ajh.26966","volume":"98","author":"SA Wang","year":"2023","unstructured":"Wang SA, et al. The international consensus classification of Eosinophilic Disorders and systemic mastocytosis. Am J Hematol. 2023;98(8):1286\u2013306. https:\/\/doi.org\/10.1002\/ajh.26966.","journal-title":"Am J Hematol"},{"issue":"7","key":"737_CR17","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.3390\/jcm10071420","volume":"10","author":"R Zanotti","year":"2021","unstructured":"Zanotti R, et al. Bone marrow mastocytosis: A diagnostic challenge. J Clin Med. 2021;10(7):1420. https:\/\/doi.org\/10.3390\/jcm10071420.","journal-title":"J Clin Med"},{"issue":"18","key":"737_CR18","doi-asserted-by":"publisher","first-page":"3769","DOI":"10.1182\/blood-2009-05-220145","volume":"114","author":"A Pardanani","year":"2009","unstructured":"Pardanani A, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood. 2009;114(18):3769\u201372. https:\/\/doi.org\/10.1182\/blood-2009-05-220145.","journal-title":"Blood"},{"issue":"7","key":"737_CR19","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/ajh.26962","volume":"98","author":"A Pardanani","year":"2023","unstructured":"Pardanani A. Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management. Am J Hematol. 2023;98(7):1097\u2013116. https:\/\/doi.org\/10.1002\/ajh.26962.","journal-title":"Am J Hematol"},{"issue":"23","key":"737_CR20","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","volume":"113","author":"K-H Lim","year":"2009","unstructured":"Lim K-H, et al. Systemic mastocytosis in 342 consecutive adults: Survival studies and prognostic factors. Blood. 2009;113(23):5727\u201336. https:\/\/doi.org\/10.1182\/blood-2009-02-205237.","journal-title":"Blood"},{"issue":"23","key":"737_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1182\/blood.v126.23.349.349","volume":"126","author":"M Jawhar","year":"2015","unstructured":"Jawhar M, et al. Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with Kit D816V+ advanced systemic mastocytosis. Blood. 2015;126(23):349\u2013349. https:\/\/doi.org\/10.1182\/blood.v126.23.349.349.","journal-title":"Blood"},{"issue":"31","key":"737_CR22","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1200\/jco.19.00640","volume":"37","author":"M Jawhar","year":"2019","unstructured":"Jawhar M, et al. Mars: Mutation-adjusted risk score for advanced systemic mastocytosis. J Clin Oncol. 2019;37(31):2846\u201356. https:\/\/doi.org\/10.1200\/jco.19.00640.","journal-title":"J Clin Oncol"},{"key":"737_CR23","doi-asserted-by":"publisher","unstructured":"Mu\u00f1oz-Gonz\u00e1lez, J.I.\u00a0et al.\u00a0(2021) \u2018Proposed global prognostic score for systemic mastocytosis: A retrospective prognostic modelling study\u2019,\u00a0The Lancet Haematology, 8(3). https:\/\/doi.org\/10.1016\/s2352-3026(20)30400-2.","DOI":"10.1016\/s2352-3026(20)30400-2"},{"key":"737_CR24","doi-asserted-by":"publisher","unstructured":"Valent, P.\u00a0et al.\u00a0(2022) \u2018Personalized management strategies in mast cell disorders: ECNM-AIM User\u2019s guide for Daily Clinical Practice\u2019,\u00a0The Journal of Allergy and Clinical Immunology: In Practice, 10(8). https:\/\/doi.org\/10.1016\/j.jaip.2022.03.007.","DOI":"10.1016\/j.jaip.2022.03.007"},{"issue":"1","key":"737_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11882-009-0080-8","volume":"10","author":"C Akin","year":"2010","unstructured":"Akin C. Anaphylaxis and mast cell disease: What is the risk? Curr Allergy Asthma Rep. 2010;10(1):34\u20138. https:\/\/doi.org\/10.1007\/s11882-009-0080-8.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"21","key":"737_CR26","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.3390\/diagnostics13213307","volume":"13","author":"T G\u00fclen","year":"2023","unstructured":"G\u00fclen T. A puzzling mast cell trilogy: Anaphylaxis, MCAS, and mastocytosis. Diagnostics. 2023;13(21):3307. https:\/\/doi.org\/10.3390\/diagnostics13213307.","journal-title":"Diagnostics"},{"issue":"9","key":"737_CR27","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/j.1398-9995.2009.02118.x","volume":"64","author":"M Niedoszytko","year":"2009","unstructured":"Niedoszytko M, et al. Mastocytosis and insect venom allergy: Diagnosis, safety and efficacy of Venom immunotherapy. Allergy. 2009;64(9):1237\u201345. https:\/\/doi.org\/10.1111\/j.1398-9995.2009.02118.x.","journal-title":"Allergy"},{"issue":"1","key":"737_CR28","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/all.13237","volume":"73","author":"S Broesby-Olsen","year":"2017","unstructured":"Broesby-Olsen S, et al. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations. Allergy. 2017;73(1):230\u20138. https:\/\/doi.org\/10.1111\/all.13237.","journal-title":"Allergy"},{"key":"737_CR29","doi-asserted-by":"publisher","unstructured":"Farmer, I. et al. (2024) \u2018Prevalence of reduced bone mineral density in indolent systemic mastocytosis: UK single-centre retrospective review\u2019 BSH24-PO32. https:\/\/doi.org\/10.1111\/bjh.19398","DOI":"10.1111\/bjh.19398"},{"key":"737_CR30","doi-asserted-by":"publisher","unstructured":"Makovoz, A.\u00a0et al.\u00a0(2021) \u2018Assessment of osteoporosis and fracture risk in mastocytosis within a North American cohort\u2019,\u00a0The Journal of Allergy and Clinical Immunology: In Practice, 9(12). https:\/\/doi.org\/10.1016\/j.jaip.2021.08.001.","DOI":"10.1016\/j.jaip.2021.08.001"},{"issue":"12","key":"737_CR31","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajh.21561","volume":"84","author":"KH Lim","year":"2009","unstructured":"Lim KH, et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, Imatinib Mesylate or 2-chlorodeoxyadenosine. Am J Hematol. 2009;84(12):790\u20134. https:\/\/doi.org\/10.1002\/ajh.21561.","journal-title":"Am J Hematol"},{"issue":"8","key":"737_CR32","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","volume":"126","author":"S Barete","year":"2015","unstructured":"Barete S, et al. Long-term efficacy and safety of Cladribine (2-CDA) in adult patients with mastocytosis. Blood. 2015;126(8):1009\u201316. https:\/\/doi.org\/10.1182\/blood-2014-12-614743.","journal-title":"Blood"},{"key":"737_CR33","doi-asserted-by":"publisher","unstructured":"Arun, V.A.\u00a0et al.\u00a0(2021) \u2018Aggressive systemic mastocytosis presenting as rapidly progressive ascites, generalised lymphadenopathy and osteosclerosis\u2019,\u00a0BMJ Case Reports, 14(2). https:\/\/doi.org\/10.1136\/bcr-2020-238034.","DOI":"10.1136\/bcr-2020-238034"},{"key":"737_CR34","doi-asserted-by":"publisher","unstructured":"Ferrari, J.\u00a0et al.\u00a0(2022) \u2018Mastocytosis: Fertility and pregnancy management in a rare disease\u2019,\u00a0Frontiers in Oncology, 12. https:\/\/doi.org\/10.3389\/fonc.2022.874178.","DOI":"10.3389\/fonc.2022.874178"},{"issue":"40","key":"737_CR35","doi-asserted-by":"publisher","first-page":"68950","DOI":"10.18632\/oncotarget.10711","volume":"8","author":"I Alvarez-Twose","year":"2016","unstructured":"Alvarez-Twose I, et al. Imatinib in systemic mastocytosis: A phase IV clinical trial in patients lacking exon 17 kit mutations and review of the literature. Oncotarget. 2016;8(40):68950\u201363. https:\/\/doi.org\/10.18632\/oncotarget.10711.","journal-title":"Oncotarget"},{"issue":"10069","key":"737_CR36","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/s0140-6736(16)31403-9","volume":"389","author":"O Lortholary","year":"2017","unstructured":"Lortholary O, et al. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: A randomised, placebo-controlled, phase 3 study. The Lancet. 2017;389(10069):612\u201320. https:\/\/doi.org\/10.1016\/s0140-6736(16)31403-9.","journal-title":"The Lancet"},{"issue":"26","key":"737_CR37","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1056\/nejmoa1513098","volume":"374","author":"J Gotlib","year":"2016","unstructured":"Gotlib J, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374(26):2530\u201341. https:\/\/doi.org\/10.1056\/nejmoa1513098.","journal-title":"N Engl J Med"},{"issue":"2","key":"737_CR38","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/leu.2017.234","volume":"32","author":"DJ DeAngelo","year":"2018","unstructured":"DeAngelo DJ, et al. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. 2018;32(2):470\u20138. https:\/\/doi.org\/10.1038\/leu.2017.234.","journal-title":"Leukemia"},{"issue":"12","key":"737_CR39","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","volume":"27","author":"DJ DeAngelo","year":"2021","unstructured":"DeAngelo DJ, et al. Safety and efficacy of avapritinib in advanced systemic mastocytosis: The phase 1 explorer trial. Nat Med. 2021;27(12):2183\u201391. https:\/\/doi.org\/10.1038\/s41591-021-01538-9.","journal-title":"Nat Med"},{"issue":"12","key":"737_CR40","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","volume":"27","author":"J Gotlib","year":"2021","unstructured":"Gotlib J, et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: Interim analysis of the phase 2 pathfinder trial. Nat Med. 2021;27(12):2192\u20139. https:\/\/doi.org\/10.1038\/s41591-021-01539-8.","journal-title":"Nat Med"},{"key":"737_CR41","doi-asserted-by":"publisher","unstructured":"Gotlib, J.\u00a0et al.\u00a0(2023) \u2018Avapritinib versus placebo in indolent systemic mastocytosis\u2019,\u00a0NEJM Evidence, 2(6). https:\/\/doi.org\/10.1056\/evidoa2200339.","DOI":"10.1056\/evidoa2200339"},{"key":"737_CR42","doi-asserted-by":"publisher","unstructured":"Taylor, F.\u00a0et al.\u00a0(2021) \u2018Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: The ADVSM-SAF and ISM-SAF\u00a9\u2019,\u00a0Orphanet Journal of Rare Diseases, 16(1). https:\/\/doi.org\/10.1186\/s13023-021-02035-5.","DOI":"10.1186\/s13023-021-02035-5"},{"key":"737_CR43","doi-asserted-by":"publisher","unstructured":"Maurer, Marcus et al. (Journal of Allergy and Clinical Immunology (2024) \u2018Exploring the Spectrum of Indolent Systemic Mastocytosis: Analysis of High-Risk Disease Features in the PIONEER Study\u2019, Journal of Allergy and Clinical Immunology, Volume 153, Issue 2, AB238. https:\/\/doi.org\/10.1016\/j.jaci.2023.11.765","DOI":"10.1016\/j.jaci.2023.11.765"},{"key":"737_CR44","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1097\/01.hs9.0000847064.38588.9b","volume":"6","author":"DJ DeAngelo","year":"2022","unstructured":"DeAngelo DJ, et al. \u2018P1049: A phase 2 study of BEZUCLASTINIB (CGT9486), a novel, highly selective, potent kit D816V inhibitor, in adults with advanced systemic mastocytosis (Apex): Methods. Baseline Data, and early insights\u2019, HemaSphere. 2022;6:939\u201340. https:\/\/doi.org\/10.1097\/01.hs9.0000847064.38588.9b.","journal-title":"Baseline Data, and early insights\u2019, HemaSphere"},{"issue":"Supplement 1","key":"737_CR45","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1182\/blood-2021-145928","volume":"138","author":"J Gotlib","year":"2021","unstructured":"Gotlib J, et al. A phase 2 study of Bezuclastinib (CGT9486), an oral, selective, and potent kit D816V inhibitor, in adult patients with advanced systemic mastocytosis (AdvSM). Blood. 2021;138(Supplement 1):3636\u20133636. https:\/\/doi.org\/10.1182\/blood-2021-145928.","journal-title":"Blood"},{"issue":"Supplement 1","key":"737_CR46","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1182\/blood-2023-178885","volume":"142","author":"P Vachhani","year":"2023","unstructured":"Vachhani P, et al. Safety and efficacy of bezuclastinib (CGT9486), a novel, highly selective, potent kit D816V tyrosine kinase inhibitor, in patients with advanced systemic mastocytosis (AdvSM): Results from part 1 of the Phase 2 Apex Trial. Blood. 2023;142(Supplement 1):4567\u20134567. https:\/\/doi.org\/10.1182\/blood-2023-178885.","journal-title":"Blood"},{"key":"737_CR47","unstructured":"Reiter, A.\u00a0et al.\u00a0(2024) \u2018Summit part 2 trial in progress: A global, randomized, double-blind, placebo-controlled, 3-part phase 2 clinical trial of bezuclastinib in adult patients with nonadvanced systemic mastocytosis.\u2019 EHA Abstract library. Abstract: PB2892."},{"issue":"Supplement 1","key":"737_CR48","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1182\/blood-2023-188904","volume":"142","author":"T Tashi","year":"2023","unstructured":"Tashi T, et al. Elenestinib, an investigational, Next Generation Kit D816V inhibitor, reduces mast cell burden, improves symptoms, and has a favorable safety profile in patients with indolent systemic mastocytosis: Analysis of the Harbor Trial. Blood. 2023;142(Supplement 1):76\u201376. https:\/\/doi.org\/10.1182\/blood-2023-188904.","journal-title":"Blood"},{"key":"737_CR49","doi-asserted-by":"publisher","unstructured":"Castells, M.\u00a0et al.\u00a0(2022) \u2018A phase 2\/3 study of blu-263 in patients with indolent systemic mastocytosis or monoclonal mast cell activation syndrome\u2019,\u00a0Journal of Allergy and Clinical Immunology, 149(2). https:\/\/doi.org\/10.1016\/j.jaci.2021.12.721.","DOI":"10.1016\/j.jaci.2021.12.721"},{"issue":"Supplement 1","key":"737_CR50","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1182\/blood-2021-150872","volume":"138","author":"MW Deininger","year":"2021","unstructured":"Deininger MW, et al. Effective control of advance systemic mastocytosis with avapritinib: Mutational analysis from the Explorer Clinical Study. Blood. 2021;138(Supplement 1):318\u2013318. https:\/\/doi.org\/10.1182\/blood-2021-150872.","journal-title":"Blood"},{"issue":"3","key":"737_CR51","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ajh.26455","volume":"97","author":"MM Patnaik","year":"2022","unstructured":"Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(3):352\u201372. https:\/\/doi.org\/10.1002\/ajh.26455.","journal-title":"Am J Hematol"},{"issue":"29","key":"737_CR52","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1200\/jco.2014.55.2018","volume":"32","author":"C Ustun","year":"2014","unstructured":"Ustun C, et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol. 2014;32(29):3264\u201374. https:\/\/doi.org\/10.1200\/jco.2014.55.2018.","journal-title":"J Clin Oncol"},{"issue":"4","key":"737_CR53","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41375-024-02186-x","volume":"38","author":"J L\u00fcbke","year":"2024","unstructured":"L\u00fcbke J, et al. Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries. Leukemia. 2024;38(4):810\u201321. https:\/\/doi.org\/10.1038\/s41375-024-02186-x.","journal-title":"Leukemia"},{"issue":"4","key":"737_CR54","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41375-024-02182-1","volume":"38","author":"DP McLornan","year":"2024","unstructured":"McLornan DP, et al. Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee. Leukemia. 2024;38(4):699\u2013711. https:\/\/doi.org\/10.1038\/s41375-024-02182-1.","journal-title":"Leukemia"},{"key":"737_CR55","unstructured":"Clinicaltrials.gov. Safety and efficacy of subcutaneous sarilumab in improving the quality of life in people with indolent systemic mastocytosis. NCT03770273."},{"issue":"5","key":"737_CR56","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/bjd\/ljad191","volume":"189","author":"F Siebenhaar","year":"2023","unstructured":"Siebenhaar F, et al. Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: A first-in-human clinical trial. Br J Dermatol. 2023;189(5):511\u20139. https:\/\/doi.org\/10.1093\/bjd\/ljad191.","journal-title":"Br J Dermatol"},{"issue":"2","key":"737_CR57","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaci.2023.10.007","volume":"153","author":"V Jain","year":"2024","unstructured":"Jain V, et al. Remibrutinib demonstrates favourable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks. J Allergy Clin Immunol. 2024;153(2):479-486.e4. https:\/\/doi.org\/10.1016\/j.jaci.2023.10.007.","journal-title":"J Allergy Clin Immunol"},{"key":"737_CR58","unstructured":"ClinicalTrials.gov. Study of TL-895 in Subjects with Myelofibrosis or Indolent Systemic Mastocytosis. NCT04655118."}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-024-00737-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-024-00737-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-024-00737-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T09:10:20Z","timestamp":1726909820000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-024-00737-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["737"],"URL":"https:\/\/doi.org\/10.1007\/s11899-024-00737-8","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]},"assertion":[{"value":"25 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"Please see attached COI:Disclosure Dr D Radia.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}